← Leaderboards
Petr O Ilyinskii
Harvard University (Medical School)
$1,394,116
Attributed
$1,394,116
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $527K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,394,116 · 4
By mechanism
R43$1,117,897 · 2
P51$276,219 · 2
Top collaborators
No co-investigators on record.
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Robert E Means$2,015,359
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusGrantImmune ResponseVaccinesAidsAnimal TissueLymphatic SystemInflammationCommunicable DiseasesBaseTechnologyImmunologyCessation Of LifeCd4 Positive T LymphocytesAnimalsBiodegradable PolymerEnzyme-Linked Immunosorbent AssayAnimal ModelAffectDisorder Later Incidence PreventionCostAntigens, ViralComputer SimulationAntibody Formation
Grant awards (6)
A SYNTHETIC NANOPARTICLE VACCINE FOR THE INDUCTION OF ANTI-NICOTINE ANTIBODIES$53,995
P51 · FY2011 · RR · contact PI
Modification of Conserved Influenza Genes Enabling their Elevated Expression$103,180
R43 · FY2008 · AI · contact PI
Novel broad spectrum vaccination against influenza$487,723
R43 · FY2006 · AI · contact PI
Novel broad spectrum vaccination against influenza$526,994
R43 · FY2005 · AI
ID SEQUENCE ELEMENT ABOVE POLYPURINE TRACT ESSENTIAL FOR SIV REPLICATION$111,112
P51 · FY2002 · RR
ID SEQUENCE ELEMENT ABOVE POLYPURINE TRACT ESSENTIAL FOR SIV REPLICATION$111,112
P51 · FY2001 · RR